drugset
drugset / Trial / NCT02231918

Study to Investigate Pharmacokinetics (PK) of Pramipexole in Pediatric Patients Who Are Individually Optimized to Stable Pramipexole Doses for the Treatment of Idiopathic Restless Legs Syndrome (RLS)

NCT02231918 ↗

Phase 2 Completed 26 enrolled Boehringer Ingelheim
Non-randomizedParallel-groupOpen-labelTreatment

Summary

Study to determine the pharmacokinetics (PK) of pramipexole (PPX) after administration of a single dose orally (p.o.) in pediatric patients with the diagnosis of RLS

Timeline

Start
2006-05
Primary completion
2007-07
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject Pramipexole Unknown 0.125 mg Oral
Subject Pramipexole Unknown 0.25 mg Oral
Subject Pramipexole Unknown 0.5 mg Oral

Indications

restless legs syndrome